# EDGAR Filing Document

**Accession Number:** 0001683541
**File Stem:** 0001279569-26-000312
**Filing Date:** 2026-4
**Character Count:** 4433
**Document Hash:** 9da0104374f8cbdd297af16490762109
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001279569-26-000312.hdr.sgml**: 20260416

**ACCESSION NUMBER**: 0001279569-26-000312

**CONFORMED SUBMISSION TYPE**: 6-K

**PUBLIC DOCUMENT COUNT**: 2

**CONFORMED PERIOD OF REPORT**: 20260416

**FILED AS OF DATE**: 20260416

**DATE AS OF CHANGE**: 20260416

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** AURORA CANNABIS INC
- **CENTRAL INDEX KEY:** 0001683541
- **STANDARD INDUSTRIAL CLASSIFICATION:** MEDICINAL CHEMICALS & BOTANICAL PRODUCTS [2833]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **STATE OF INCORPORATION:** A1
- **FISCAL YEAR END:** 0331

**FILING VALUES:**
- **FORM TYPE:** 6-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-38691
- **FILM NUMBER:** 26867821

**BUSINESS ADDRESS:**
- **STREET 1:** 2207 90B STREET SW
- **CITY:** EDMONTON
- **STATE:** A0
- **ZIP:** T6X 1V8
- **BUSINESS PHONE:** 604-362-5207

**MAIL ADDRESS:**
- **STREET 1:** 409 GRANVILLE STREET
- **STREET 2:** SUITE 1700
- **CITY:** VANCOUVER
- **STATE:** A1
- **ZIP:** V6C 1T2

**UNITED STATES<br> SECURITIES AND EXCHANGE COMMISSION<br> Washington, D.C. 20549**

**FORM 6-K**

**REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16<br> UNDER THE SECURITIES EXCHANGE ACT OF 1934**

For the month of **April 2026**

Commission File No. **001-38691**

**<u>AURORA CANNABIS INC.</u>** ****<br> (Translation of registrant's name into English)

**2207 90B St. SW <br> Edmonton, Alberta T6X 1V8 <br> Canada**<br> (Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F

Form 20-F ☐ **Form 40-F ☒**

**INCORPORATION BY REFERENCE**

This Form 6-K is hereby filed and incorporated by reference in the registrant's Registration Statements on Form F-10 (File No. 333-284958) and on Form S-8 (File No. 333-282253).

**SUBMITTED HEREWITH**

---

| | |
|:---|:---|
| **Exhibits** | **Description** |
| [99.1](ex991.htm) | [Material Change Report dated April 16, 2026](ex991.htm) |

---

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

**AURORA CANNABIS INC.**

/s/ *Miguel Martin*

<br> Miguel Martin<br> Chief Executive Officer

Date: April 16, 2026

## Exhibit 99.1

**Exhibit 99.1**

**FORM 51-102F3**

***MATERIAL CHANGE REPORT***

**Item 1 Name and Address of Company**

Aurora Cannabis Inc. ("**Aurora**" or the "**Company**")

2207-90b Street SW

Edmonton, Alberta

T6X 1V8

**Item 2 Date of Material Change**

April 14, 2026

**Item 3 News Release**

A press release describing the material change was disseminated by Aurora on April 15, 2026 through Cision PR Newswire and can be found on SEDAR+ at <u>www.sedarplus.ca</u>.

**Item 4 Summary of Material Change**

A wholly owned subsidiary of Aurora ("**Aurora Sub**") indirectly purchased 100% of the shares of 9869247 Canada Limited ("**Safari Flower Company**"), an established EU GMP certified cannabis cultivator and manufacturer. Aggregate consideration is valued at $26.5 million, subject to customary adjustments, and inclusive of a cash payment of $2 million that is contingent on satisfaction of certain conditions (the "**Transaction**").

**Item 5 Full Description of Material Change**

**5.1 Full Description of Material Change**

On April 14, 2026, Aurora Sub indirectly purchased 100% of the shares of Safari Flower Company for aggregate consideration valued at $26.5 million, inclusive of a cash payment of $2 million that is contingent on satisfaction of certain conditions. As consideration on closing, Aurora (i) issued the selling shareholder 2,417,180 common shares; and (ii) paid the selling shareholder $15 million in cash, subject to customary adjustments post closing.

**5.2 Disclosure for Restructuring Transactions**

Not applicable*.*

**Item 6 Reliance on subsection 7.1(2) of National Instrument 51-102**

Not applicable*.*

**Item 7 Omitted Information**

Not applicable*.*

 

**Item 8 Executive Officer**

Further information regarding the matters described in this report may be obtained from Nathalie Clark, Executive Vice President, General Counsel & Corporate Secretary who is knowledgeable about the details of the Transaction and may be contacted at nathalie.clark@auroramj.com.

**Item 9 Date of Report**

April 16, 2026.